WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Efruxifermin

Governed registry record

4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Approved source records

  1. A systematic review and meta-analysis of efruxifermin's efficacy in improving liver fibrosis in patients with NASH/MASH.

    DOI: 10.3389/fphar.2025.1594091

    Source identity and connection checked by Codex (AI).

  2. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.

    DOI: 10.1056/nejmoa2502242

    Source identity and connection checked by Codex (AI).

  3. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.

    DOI: 10.1038/s41591-021-01425-3

    Source identity and connection checked by Codex (AI).

  4. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.

    DOI: 10.1016/s2468-1253(23)00272-8

    Source identity and connection checked by Codex (AI).

Legacy research context

Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.

Researchers represented

  • Harrison SA
  • Frias JP
  • Neff G
  • Abrams GA
  • Lucas KJ
  • Sanchez W
  • Gogia S
  • Sheikh MY
  • Behling C
  • Bedossa P
  • Shao L
  • Chan D
  • Fong E
  • de Temple B
  • Shringarpure R
  • Tillman EJ
  • Rolph T
  • Cheng A
  • Yale K
  • HARMONY Study Group
  • Noureddin M
  • Rinella ME
  • Chalasani NP
  • Neff GW
  • Rodriguez ME
  • Rudraraju M
  • Patil R
  • Burch M
  • Chan DC
  • Zari A
  • Jain M
  • Ruane PJ
  • Freilich BL
  • Behling CA
  • Hu C
  • Rolph TP
  • Li S
  • Zou W
  • Zhou Y
  • Li W
  • Liao W
  • Li T
  • Zhang Z